AME Logo

Related Materials

23rd European Meeting on HIV & Hepatitis 2025

Show local (UTC) times

14:00

Opening of the Meeting

14:00

Opening Words

14:05

Welcome to Barcelona

14:15

Session 1: Implementation of HIV Prevention in Europe

14:15

Chair

14:15

Efficacy, Toxicity and Adherence Considerations

14:30

Logistical and Infrastructure Considerations

14:45

Price Considerations

15:45

Coffee Break & Poster Viewing 1

16:45

Session 2: Abstract-Driven Session - Virological Control

16:15

#1 #1 Comparable Dynamics of Cell-Associated HIV-RNA, Total and Intact Proviral HIV-1 DNA in Virologically Suppressed People with HIV Switching to 2DR or Continuing 3DR Over an 18-Month Follow-Up

Abstract

16:25

#2 #2 In Addition to Their Ability to Induce Resistance to Antiretrovirals, Integrase Inhibitors and Lenacapavir Resistance Mutations Enable HIV-1 to Evade Recognition by the Innate Immune System

Abstract

16:35

#3 #3 Unveiling Novel Microbiome Signatures for Natural Virological Control in HIV-1 Elite Controllers

Abstract

16:45

Chair

16:45

#4 #4 WG-am: A Novel Antiviral Dipeptide from Elite Controllers as a Promising Vaginal Microbicide for HIV Prevention

Abstract

17:15

Guided Poster Tour 1

17:15

Chair

17:15

#38 Optimizing a HIV-1 Genotypic Resistance Assay for Diverse Subtypes and Illumina Sequencing

Abstract

17:25

#42 Automated Reflex HIV Screening Based on Diagnostic Indicators: A New Perspective from Clinical Microbiology

Abstract

17:35

#64 Selection Rate of Resistance to Long-Acting CAB/RPV in a Real Life French Cohort with Strict Inclusion and Monitoring Criteria

Abstract

17:45

#66 HBV Reactivation Post-Switch to HBV-Inactive ART: A Scoping Review

Abstract

17:55

#68 Add-On Efficacy of Doravirine to Antiretroviral Treatment in People Living with HIV-1 Harboring a Classical Virological Failure and Those with Persistent Low-Level Viremia

Abstract

18:05

#70 Very Slow Decay of Total HIV-1 DNA During Suppressive ART: A Routine Cohort Report

Abstract

Downloads